Benjamin Brooks

Statistics

Publications

Citations

H-Index

Active since

1977

Affiliations

University of Maryland, Baltimore(Current)

Alexion Pharmaceuticals (United States)

University of Wisconsin–Madison

Yale University

Fondazione IRCCS Istituto Neurologico Carlo Besta

Benjamin Brooks is an author at University of Maryland, Baltimore specializing in pharmacotherapy, clinical pharmacology, and neurologic pharmacotherapy.

ORCID

Publications per year

1977–2020

Publications

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1995 · 1.9K citations

Pharmacy, Neurology, Pharmacotherapy +15

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1998 · 512 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

K. P. Johnson, Benjamin Brooks, Corey C. Ford et al. · Multiple Sclerosis Journal · 2000 · 227 citations

Pharmacy, Neurology, Pharmacotherapy +16

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

K. P. Johnson, Benjamin Brooks, Corey C. Ford et al. · Multiple Sclerosis Journal · 2000 · 188 citations

Pharmacy, Neurology, Pharmacotherapy +16

1–5 of 13